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The tools for managing retinoblastoma have been increasing in the past decade. While globe-salvage still relies heavily on
intravenous chemotherapy, tumors in advanced stage that failed chemotherapy are now referred for intra-arterial chemotherapy
(IAC) to avoid enucleation. However, IAC still has many obstacles to overcome. We present an update on the indications,
complications, limitations, success, and technical aspects of IAC. Given its safety and high efficacy, it is expected that IAC will
replace conventional strategies and will become a first-line option even for tumors that are amenable for other strategies.

1. Introduction

2. Tools for Management

Retinoblastoma is the most common intraocular malignancy
in children [1], leading to death within 1-2 years if left
untreated [1]. Survival after diagnosis mirrors economic
development and ranges from 30% in Africa to 60% in
Asia and 95–97% in Europe and North America [1]. Over
the last few years, intra-arterial chemotherapy (IAC) has
surfaced as a promising treatment alternative for advanced
and refractory retinoblastomas. The main reason behind
the increased popularity of IAC is to avoid enucleation.
Today, IAC is increasingly gaining ground as an effective
and safe treatment in the management of retinoblastoma
[2, 3]. However, IAC still has many obstacles to overcome.
We present an update on IAC for retinoblastoma apropos the
techniques, limitations, and outcomes.

Establishing an accurate diagnosis and staging the disease are
the first steps in the management of retinoblastoma to avoid
mistreating the patient with chemotherapy. The physician
cannot always easily distinguish between retinoblastoma and
mimicking lesions, called pseudoretinoblastomas. In a review
of 2775 patients referred for management for retinoblastoma,
78% were confirmed with retinoblastoma while 22% had
pseudoretinoblastomas [4]. Pseudoretinoblastoma comprises
a range of diagnosis, such as persistent fetal vasculature,
Coats disease, vitreous hemorrhage, toxocariasis, and familial
exudative vitreoretinopathy [4]. The prevalence of these
mimickers depends mostly on the child’s age [4]. The
tools for management of retinoblastoma include enucleation,
radiotherapy (teletherapy or brachytherapy), chemotherapy,
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Table 1: The International Classification of Retinoblastoma (IRCB) [7].

Group

Defining features

A
B

Tumor <3 mm in size
Tumor >3 mm in size or macular Rb location; juxtapapillary Rb location, clear subretinal fluid ≤3 mm from margin
Tumor with focal seeding: subretinal seeds ≤3 mm from Rb; vitreous seeds ≤3 mm from Rb; subretinal and vitreous
seeds ≤3 mm from Rb
Tumor with diffuse seeding: subretinal seeds >3 mm from Rb; vitreous seeds >3 mm from Rb; subretinal and vitreous
seeds >3 mm from Rb
Extensive tumor occupying >50% of the globe or neovascular glaucoma; invasion of postlaminar optic nerve,
choroid, sclera, orbit, anterior chamber; massive intraocular hemorrhage

C
D
E
∗

Rb: retinoblastoma.

cryotherapy, laser photocoagulation, and transpupillary thermotherapy [5]. However, globe salvage still relies heavily on
chemotherapy [6].
Chemotherapy can use various routes, such as intravenous, periocular, intravitreal, or intra-arterial. The chemotherapy strategy depends mostly on the severity of the ocular
tumor, for which the most commonly used classification is the
International Classification of Retinoblastoma [7] (Table 1).
This presurgical classification is favored by many authors as
it has been found predictive of treatment success following
intravenous chemotherapy (IVC) [6]. Ocular tumors are
separated into five letter groups from A to E of increasing
disease progression. The grouping is based on specific ophthalmoscopic features, such as the presence of vitreous or
subretinal seeding. Each group has a corresponding risk of
treatment failure and subsequent enucleation, with the lowest
risk in group A and the highest risk in group E [7].

3. Update on the General Treatment Strategy
IVC has been effective for the control of intraocular disease,
prevention of metastasis, and reduction in the prevalence of
pinealoblastoma and long-term second malignant neoplasms
[8]. It has the additional benefits of minimal systemic toxicity
and no adverse ocular effects [8]. Therefore, IVC is recommended as the first line treatment for germ-line mutation
retinoblastomas (bilateral, familial), particularly to protect
patients from pineoblastoma and second cancers and, in
addition, to achieve control of the intraocular retinoblastoma
and to prevent metastasis [6].
On the other hand, non-germ-line mutation retinoblastomas (unilateral) are best managed with IAC, if the disease
is judged to be beyond control by local treatment modalities
such as laser photocoagulation, thermotherapy/cryotherapy,
or plaque radiotherapy. IAC is also indicated for unilateral
advanced disease. Unilateral retinoblastoma of groups D and
E was classically managed with enucleation, but now it can
be managed with globe-conserving strategies, that is, IVC
combined with IAC [8]. Advanced cases may also benefit
from periocular chemotherapy combined with IVC.
Finally, intravitreal chemotherapy can be used as a last
resort, following incomplete control with IAC [8], specifically
when recurrent vitreous seeds are present. In fact, the main
reason for IAC failure and subsequent enucleation is the
recurrence of subretinal or vitreous seeds. We might be able

to overcome this problem of recurrent subretinal/vitreous
seeds with the use of intravitreal melphalan, with or without
topotecan. Reports of higher rates of global salvage using
multimodality treatments are already available [9, 10]. Bilateral groups D and E retinoblastoma cases should receive
an additional subtenon carboplatin boost for improved local
control [8]. The most common causes for undergoing enucleation are tumor size, poor visual improvement potential, and
risk of metastatic disease [8].

4. Update on Technical Aspects
The IAC technique usually relies on navigating through the
ipsilateral internal carotid artery to selectively catheterize
the ostium of the ophthalmic artery (OA) (with a Prowler10 microcatheter, Cordis Neurovascular). This is followed
by a superselective injection to confirm the position of the
microcatheter and to ascertain the lack of reflux into the
internal carotid artery [11]. If a direct catheterization of
OA is not successful, two alternatives routes can be safely
and effectively used [12]. The first is the catheterization
of the OA through the middle meningeal artery (MMA),
if a communicating branch between the 2 systems is well
developed [11]. If an anastomosis is not sufficiently developed,
the “Japanese technique” can be used. This technique involves
rapid chemotherapy delivery through a catheter placed in the
internal carotid artery, at the takeoff of the OA, with balloon
occlusion of distal flow [13].
At present, the superiority of direct catheterization
over the Japanese technique is uncertain. In theory, direct
catheterization minimizes the systemic absorption and maximizes the drug availability at the tumor bed. Even though this
approach is technically difficult, the rate of technical success
in expert hands is as high as 98.5% to 100% [11], supporting
the evidence of a learning curve. Limitations include the risk
of endothelial injury [14] and OA thrombosis, necessitating
the use of alternative routes (described above). The Japanese
technique or balloon-assisted catheterization also carries a
technical challenge and is limited by the risk of ischemic and
thromboembolic events.
In a retrospective review, Klufas and colleagues [12]
reported tumor control in 17 out of 18 eyes, using IAC via
the alternative routes, at a mean followup of 18.9 months.
The treatment routes included catheterization via the MMA,
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balloon-assisted infusion alone, and balloon-assisted infusion in conjunction with direct OA catheterization. Sometimes a combination of two or all three modalities was necessary. The authors concluded that when direct catheterization
is not possible, the alternative techniques can be used safely
to preserve vision with acceptable side effects [12].

5. Outcomes of IAC: Update on Success
and Advantages
IAC offers the advantage of decreasing the systemic distribution of the given drug, consequently minimizing drug-related
toxicities including neutropenia, anemia, and secondary
neoplasms [15]. Reducing the systemic absorption allows for
the use of highly potent drugs, namely, melphalan [11], which
is proven to be the most effective chemotherapeutic agent
against retinoblastoma. Melphalan is very toxic at therapeutic
levels when used systemically [16], but it can be safely used via
the intra-arterial route [11]. Undeniably, melphalan remains
as the ideal agent for IAC due to its efficacy and short half-life
[17, 18]. Melphalan is often used alone but can be combined
with topotecan for advanced cases with extensive vitreous
seeds [17, 19]. Another advantage of minimizing the systemic
toxicity is the decreased need for hospitalization, allowing
the child to be discharged the same day, in the absence
of intraoperative vascular complications. Furthermore, IAC
allows the administration of significantly higher doses of
chemotherapy directly to the tumor bed. This enhances the
biological effect, improves the tumor control, and, thus,
reduces the rate of recurrence [15].
For all the reasons discussed above, IAC has emerged
as an appealing approach in the management of retinoblastoma. However, it is important that these advantages offer
increased survival and better quality of life. So far, IAC has
achieved impressive results in the treatment of refractory
retinoblastomas, shrinking tumor size, and decreasing the
rate of enucleation [3, 17, 18, 20, 21]. The superiority of
IAC lies in its unparalleled ability to cure resistant tumors,
using only 1 chemotherapeutic agent most of the time.
Gobin et al. [17] reported successful catheterization in 98%
of procedures with an ocular survival rate at 2 years of
82%, when IAC was the primary treatment, and 58%, when
it was secondary treatment (after external beam radiation
or systemic chemotherapy). Peterson et al. [21] treated 17
eyes, 16 of which had already failed other modalities, with
intra-arterial melphalan, dramatically reducing the rate of
enucleation from 100% to 23.5%. Shields et al. [18] found
primary therapy IAC to successfully achieve globe salvage in
100% of group C, 100% of group D, and 33% of group E eyes. In
the same report [18], globe salvage was successfully achieved
in 50% of cases when IAC was a secondary treatment.
In another retrospective review of 70 eyes (60 patients),
IAC as a primary therapy achieved globe salvage in 100% of
group B, 100% of group C, 94% of group D, and 36% of group
E [6]. Of all 70 eyes, complete regression was achieved for
solid tumors in 48 of 51 eyes (94%), subretinal seeds in 40
of 42 eyes (95%), and vitreous seeds in 34 of 39 eyes (87%)
[6]. After a mean followup of 19 months, authors reported

Figure 1: Fundoscopic exam revealing an intraocular retinoblastoma before treatment with intra-arterial chemotherapy.

globe salvage in 72% of primary-treated cases and 62% of
secondary-treated cases. Failure and subsequent enucleation
were due to tumor recurrence in only one case of primary
therapy IAC, whereas the other cases of failure were due to
recurrent subretinal or vitreous seeding, across all groups,
with the majority in advanced group E. Furthermore, after
2 years of followup, the authors did not find any evidence of
retinoblastoma metastasis or of a second cancer. No deaths or
life-threatening complications have been reported.
A suitable option to avoid enucleation after IAC failure
would be the use of intravitreal melphalan, with or without
topotecan, for extensive vitreous seeding. This technique has
been reported to achieve up to 100% control of vitreous seeding [9, 10, 22]. It is also reported that combined intravitreal
chemotherapy and IAC for advanced group D and E eyes can
lead to globe salvage in 57% of the cases [23]. This is extremely
important, as these patients often have bilateral disease and
would otherwise be destined for systemic chemotherapy
with enucleation. Finally, IAC was shown to be effective
in retinoblastomas with retinal detachment. Partial retinal
detachment showed complete resolution, and complete reattachment was noted in most cases of full retinal detachment
[23]. We present one illustrative case (Figures 1, 2, and 3).

6. Updates on Limitations
6.1. General Limitations. IAC has some limitations. It is less
effective for advanced group E eyes (as reported above)
and for tumors with vitreous seeding (higher recurrence
rate). It was also theorized that the absence of systemic
absorption, while being advantageous for reducing toxicity, leads to inadequate elimination of micrometastasis and
extraocular tumor cells [15]. Without enucleation, tumor
invasion and histopathologic features suggestive of metastasis
cannot be assessed. Therefore, the patient would not receive
the indicated adjuvant systemic chemotherapy that he or she
would have otherwise received if enucleation had occurred.
Likewise, when compared with systemic chemotherapy, IAC
might not provide sufficient protection against pineoblastoma and secondary tumors, due to the lack of adequate
systemic absorption of the drug [11]. This risk, however, is
mostly present in children with germ-line mutations. Of all
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(a)

(b)

Figure 2: Digital subtraction angiography showing superselective catheterization with melphalan injection of the ophthalmic artery.

where globe-salvaging options are readily available, it is still
widely used in developing countries, where children have no
access to sophisticated tertiary centers.

Figure 3: Fundoscopic exam revealing the same patient with
intraocular retinoblastoma after treatment with intra-arterial
chemotherapy.

the limitations to date, the most concerning issue that IAC
faces to date is the risk of metastatic disease.
6.2. Economical Burden. Despite the comparable cost of
systemic chemotherapy and IAC per episode, the current
strategy of multiple planned IAC sessions makes it significantly more costly [24]. In fact, a study published in 2012
reported that the lowest-cost treatment strategy per episode
of care is enucleation ($48,000), followed by focal laser
therapy ($100,250), systemic chemotherapy alone ($253,000),
systemic chemotherapy with planned enucleation ($281,000),
and lastly IAC with melphalan ($160,000 for 3 cycles, $310,000
for 6 cycles) [24]. IAC can cost up to $430,000 for bilateral
cases. These costs reflect the hospital charges per episode
of care and do not include the costs of follow-up visits,
complications, and nonmedical indirect costs [24]. Although
enucleation is more cost effective, it should be used as a
last resort, given the risk of potential contralateral disease
and the problem of leaving the child with monocular vision.
Enucleation decreases visual acuity (lack of binocular summation) and the visual field, impairs space orientation and
depth perception, and has psychological effects on the child.
While enucleation is less favored in developed countries,

6.3. Complications. Complications following IAC can result
from the technique itself, the chemotherapeutic agents, or
both (Table 2). The complications attributed to the technique
are iodine allergies, complications at the femoral puncture
site, and intraoperative endovascular complications. In the
current literature, thromboembolic and hemorrhagic strokes
have rarely occurred [11] with carotid vascular spasm, stroke,
and MRI displaying focal perfusion defects [8]. Transient
pancytopenia from bone marrow suppression may occur,
but neutropenia and anemia rarely require intervention.
Local, minor ocular toxicities include eyelid edema, forehead
erythema, thinning or loss of eyelashes, blepharoptosis, and
transient ocular dysmotility [17, 18], which are all usually
transient. Major ocular toxicities are mostly the result of
vascular complications involving the retinal, ophthalmic, and
choroidal arteries.
Munier et al. [25] reported that 23% (3/13) of patients had
choroidal ischemia or retinal arteriolar embolism. Shields
et al. [18] reported choroidal vasculopathy or retinal artery
occlusion in 35% (6/17) of cases. Muen et al. [28] reported
ocular side effects of cranial nerve palsy (40%), orbit/eyelid
edema (20%), retinal detachment (7%), vitreous hemorrhage
(27%), and retinal pigment epithelial changes (47%). The retinal pigment epithelial changes could be related to previous
retinal detachment or choroidal vascular compromise [8]. In
a more recent study [6], the main complications following
IAC, per catheterization, included transient eyelid edema
(5%), blepharoptosis (5%), forehead hyperemia (2%), vitreous
hemorrhage (2%), branch retinal artery obstruction (1%),
ophthalmic artery spasm with reperfusion (2%), ophthalmic
artery obstruction (2%), partial choroidal ischemia (2%), and
optic neuropathy (<1%). There were no patients with stroke,
seizure, neurologic impairment, limb ischemia, secondary
leukemia, metastasis, or death [6]. Furthermore, the authors
report that the combined incidence of ophthalmic, retinal,
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Table 2: Complications of intra-arterial chemotherapy for retinoblastoma in the literature.
Number of
patients

Choroidal
ischemia (%)

Munier et al. [25]

13

23%

Shields et al. [18]

17

35%

Studies

Bayar et al. [26]

15

Shields et al. [6]

70

Tsimpida et al. [27]

12

Gobin et al. [17]

98

Retinal
detachment

7%

33%

Eyelid edema

20%

(i) CN palsy 7%
(ii) Vitreous hemorrhage 27%
(iii) Retinal pigment epithelial change
47%

14%

(i) Blepharoptosis 14%
(ii) Forehead hyperemia 4%
(iii) Vitreous hemorrhage 6%
(iv) Ophthalmic artery obstruction 4%

8%

and choroidal vascular ischemia has reduced to 1% [6], again
pointing toward the presence of a learning curve.
Management of a child with retinoblastoma involves
a balance of patient life with globe salvage and ultimate
visual potential [26, 29]. While intravenous chemotherapy
is known to have no local toxic effects on the eye related
to vision [30], the visual outcome after IAC is not well
evaluated. The relevant question is whether sparing the globe
and using IAC translate to visual success. Munier et al.
[25] found 31% (4/13) of patients receiving IAC retained
vision of 20/50 or better but did not state the proportion
of patients with foveae involvement before treatment, which
is an independent predictor of poor vision [30]. Tsimpida
and colleagues examined the visual outcome in patients with
refractory retinoblastoma who had previously undergone
systemic chemotherapy, with or without local treatment, and
were subsequently treated with IAC [27]. Five of twelve eyes
(42%) demonstrated severe visual loss at last followup. The
reported causes were retinal detachment (1 eye, 20%) and
choroidal ischemia involving the foveae (4 eyes, 80%). All 3
patients who had difficulties or vasospasm during catheterization and all patients who received the nonage-adjusted
dose of melphalan suffered from visual loss, while those who
received the age-adjusted dose did not. The authors suggested
any form of radiation before IAC is associated with worse
complications, and despite the fact that the exact mechanism
of vision deterioration after IAC is unknown, melphalan use
and difficulty catheterizing the OA are compelling factors.
Thus, based on these findings, an optimal melphalan dose
needs to be determined, where maximal tumor control and
preservation of visual function are achieved [27]. One final
problem that remains with IAC is the repetitive exposure to
ionizing radiation, which could potentially harm the thyroid,
bone marrow, and other susceptible organs. This is one of the
areas where advances are needed to avoid excess exposure
to radiation in our young patients. However, it is still not
clear whether repetitive exposure to low dose radiation has
an additive effect or not.

Other

Total visual loss 4%
14%

7. Conclusion
IAC has emerged as a remarkably effective strategy for
treating retinoblastoma. IAC is effective as both primary
and secondary treatment. Given its reported safety and high
efficacy, it is expected that IAC will replace conventional
strategies and will become a first-line option, even for tumors
amenable to other strategies.
As with the introduction of any novel treatment, studies show that technical complications are decreasing with
growing experience, supporting the existence of a learning
curve. IAC has allowed eyes that would have been enucleated
in the past to be salvaged, with the vast majority of treated
patients today retaining their eyes. In the future, even more
globes will be salvaged, since the combination of IAC with
intravitreal chemotherapy and other modalities is achieving
higher success and superior tumor control.
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